エストラムスチン
関連文献

“The mechanism of action of estramustine”. Semin. Oncol. 10 (3 Suppl 3):  21–6. (September 1983). PMID 6364362.
“Estramustine phosphate (Estracyt): experimental and clinical studies in Europe”. Semin. Oncol. 10 (3 Suppl 3):  27–33. (September 1983). PMID 6364363.
“Metabolic aspects and actions unique to Estracyt”. Semin. Oncol. 10 (3 Suppl 3):  3–15. (September 1983). PMID 6364364.
“Immunological effects of diethylstilbestrol and estramustine phosphate”. Scand J Urol Nephrol Suppl 83:  1–32. (1984). PMID 6387896.
“Estramustine phosphate sodium”. Drug Intell Clin Pharm 18 (5):  368–74. (May 1984). doi:10.1177/106002808401800502. PMID 6373212.
“Metabolic parameters of Estracyt pertinent to its effects in prostatic cancer”. Urology 23 (6 Suppl):  11–21. (June 1984). doi:10.1016/S0090-4295(84)80092-8. PMID 6375075.
“Clinical pharmacokinetics of estramustine phosphate”. Urology 23 (6 Suppl):  22–7. (June 1984). doi:10.1016/S0090-4295(84)80093-X. PMID 6375076.
“Specific binding of estramustine to prostatic proteins”. Urology 23 (6 Suppl):  34–8. (June 1984). doi:10.1016/S0090-4295(84)80095-3. PMID 6375077.
“Immunologic effects of estramustine phosphate”. Urology 23 (6 Suppl):  39–45. (June 1984). doi:10.1016/S0090-4295(84)80096-5. PMID 6375078.
“Mode of action of Emcyt”. Urology 23 (6 Suppl):  46–8. (June 1984). doi:10.1016/S0090-4295(84)80097-7. PMID 6375079.
“Preclinical pharmacology and toxicology of estramustine phosphate”. Urology 23 (6 Suppl):  6–10. (June 1984). doi:10.1016/S0090-4295(84)80091-6. PMID 6375082.
“Clinical toxicity and long-term results of Emcyt therapy for prostate cancer”. Urology 23 (6 Suppl):  73–7. (June 1984). doi:10.1016/S0090-4295(84)80103-X. PMID 6375085.
“Mode of action of estramustine phosphate in hormone dependent and hormone non-dependent prostate cancer”. Prog. Clin. Biol. Res. 185A:  197–202. (1985). PMID 3898129.
“Estracyt--mode of action and clinical experience”. Prog. Clin. Biol. Res. 243B:  215–9. (1987). PMID 3309981.
“A current review of the clinical experience with Estracyt”. Prog. Clin. Biol. Res. 243B:  221–5. (1987). PMID 3309982.
“Estramustine-binding protein in rat and human prostate”. Scand J Urol Nephrol Suppl 107:  56–8. (1988). PMID 3287598.
“Intracellular effects of estramustine (Estracyt/Emcyt)”. Prog. Clin. Biol. Res. 303:  169–75. (1989). PMID 2674983.
“Estramustine--a nitrogen mustard/steroid with antimicrotubule activity”. Pharmacol. Ther. 43 (3):  299–319. (1989). doi:10.1016/0163-7258(89)90012-0. PMID 2682681.
“Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma”. Int Urol Nephrol 21 (4):  393–7. (1989). doi:10.1007/BF02559635. PMID 2693392.
“Mechanisms of action and clinical uses of estramustine”. Cancer Invest. 8 (3–4):  375–80. (1990). doi:10.3109/07357909009012056. PMID 2207764.
“The present role of estramustine phosphate in advanced prostate cancer”. Prog. Clin. Biol. Res. 370:  323–41. (1991). PMID 1924466.
“Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer”. Prostate Suppl 4:  105–10. (1992). doi:10.1002/pros.2990210516. PMID 1574449.
“Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug”. Pharmacol. Ther. 56 (3):  323–39. (December 1992). doi:10.1016/0163-7258(92)90023-S. PMID 1301594.
“Estramustine revisited”. Cancer Treat. Res.. Cancer Treatment and Research 78:  163–84. (1995). doi:10.1007/978-1-4615-2007-8_8. ISBN 978-1-4613-5829-9. PMID 8595142.
“Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer”. Drugs Aging 7 (1):  49–74. (July 1995). doi:10.2165/00002512-199507010-00006. PMID 7579781.
“Estramustine-based chemotherapy”. Semin. Urol. Oncol. 15 (1):  13–9. (February 1997). PMID 9050135.
“Pharmacokinetics and pharmacodynamics of estramustine phosphate”. Clin Pharmacokinet 34 (2):  163–72. (February 1998). doi:10.2165/00003088-199834020-00004. PMID 9515186.
“Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer”. Int. J. Urol. 8 (2):  33–6. (February 2001). doi:10.1046/j.1442-2042.2001.00254.x. PMID 11240822.
Simpson, D; Wagstaff, AJ (2003). “Estramustine Phosphate Sodium”. American Journal of Cancer 2 (5):  373–390. doi:10.2165/00024669-200302050-00013.
“The use of estramustine phosphate in the modern management of advanced prostate cancer”. BJU Int. 108 (11):  1782–6. (December 2011). doi:10.1111/j.1464-410X.2011.10201.x. PMID 21756277.
“Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis”. Medicine (Baltimore) 95 (39):  e4801. (September 2016). doi:10.1097/MD.0000000000004801. PMC 5265899. PMID 27684806. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265899/.
Inoue, Takahiro (2018). “Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer”. Hormone Therapy and Castration Resistance of Prostate Cancer. pp. 249–256. doi:10.1007/978-981-10-7013-6_26. ISBN 978-981-10-7012-9
リン酸が外れたエストラムスチン
（細胞増殖抑制性活性代謝物の一つ）
エストロムスチンの構造式
17位の2級アルコールが酸化されケト基に変化している。
エストラジオールはエストロゲン作用を示す代謝産物である。
前立腺癌男性におけるEMP 280mg/日 経口投与時のエストラジオールおよびテストステロン値（n = 11）
ヒトにおけるエストラムスチンリン酸エステルの代謝経路